AstraZeneca discontinues MEDI-528

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it discontinued development of MEDI-528 due to the product's "lack of

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE